Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/2700
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorPASOTO, Sandra G.-
dc.contributor.authorRIBEIRO, Ana C.-
dc.contributor.authorVIANA, Vilma S. T.-
dc.contributor.authorLEON, Elaine P.-
dc.contributor.authorBUENO, Cleonice-
dc.contributor.authorNETO, Mauricio Levy-
dc.contributor.authorPRECIOSO, Alexander R.-
dc.contributor.authorTIMENETSKY, Maria do Carmo S.-
dc.contributor.authorBONFA, Eloisa-
dc.date.accessioned2013-10-11T21:16:37Z-
dc.date.available2013-10-11T21:16:37Z-
dc.date.issued2012-
dc.identifier.citationARTHRITIS AND RHEUMATISM, v.64, n.10, suppl.S, p.S928-S929, 2012-
dc.identifier.issn0004-3591-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/2700-
dc.description.abstractBackground/Purpose: Despite WHO recommendations about the A/California/7/2009/H1N1-like virus vaccination, there are no studies evalu- ating its possible influence on clinical manifestations and autoantibody profile in (primary) Sjögren’s syndrome (SS). Objectives: To evaluate short/long-term effect of influenza A/California/7/2009/H1N1-like virus vaccination on clinical manifestations and autoantibody profile in SS. Methods: Thirty-six SS patients (The American-European Consensus Group Criteria, 2002) and 36 gender-, age-, matched-healthy controls were evaluated before and 21-days after vaccination with unadjuvanted influenza A/H1N1-like virus regarding seroprotection/seroconversion, factor increase in geometric mean titre (FI-GMT) and side effects. New onset of parotiditis, arthritis, vasculitis, pneumonitis or neurological disorders and autoantibody profile [antinuclear antibodies (ANA), rheumatoid factor (RF), anti-dsDNA, anti-Ro(SS-A)/La(SS-B), anti-alpha-fodrin, anti-RNP, anti-Sm and anticar-diolipin] were assessed before, 21-days and 1-year after vaccination. Results: Patients and controls had similar rates of seroconversion (78 vs. 69%, p=0.42), seroprotection (83 vs. 72%, p=0.26) and FI-GMT (p=0.85). Pre-vaccination evaluation revealed that disease duration, glucocorticoid (mean dose 10.15.1 mg/day), methotrexate (up to 17.5 mg/week) or azathioprine (up to 100 mg/day) did not affect seroconversion (p> 0.05). Regarding short-term analysis, no change in the frequency or levels of autoantibodies was observed (p>0.05) and only mild side effects were observed in comparable rates to controls (p> 0.05). At 1-year follow-up, the rate of new disease flares was similar to the previous year (11 vs. 19%, p 0.51) and four seroconverted patients developed positivity to one of the following specificities: anti-Ro/SS-A, anti-La/SS-B, anti-alpha-fodrin, or IgM anticardiolipin. None developed other specific lupus autoantibodies. Of note, a significant increase in the mean levels of anti-Ro/SS-A (p< 0.0001) and anti-La/SS-B (p< 0.002) was detected after 1-year with no change in the other autoantibodies. Conclusion: This is the first study to indicate that influenza A/H1N1 vaccine induces long-term changes in autoantibody profile restricted to SS spectrum without a deleterious effect in disease course.-
dc.description.sponsorshipFAPESP grant: 2010/10749-0.-
dc.language.isoeng-
dc.publisherWILEY-BLACKWELL-
dc.relation.ispartofArthritis and Rheumatism-
dc.rightsrestrictedAccess-
dc.titleLong-Term Changes in Autoantibody Profile After Pandemic Unadjuvanted Influenza A/H1N1 Vaccine in Sjogren's Syndrome-
dc.typeconferenceObject-
dc.rights.holderCopyright WILEY-BLACKWELL-
dc.description.conferencedateNOV 09-14, 2012-
dc.description.conferencelocalWashington - DC, EUA-
dc.description.conferencenameAnnual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP)-
dc.subject.wosRheumatology-
dc.type.categorymeeting abstract-
dc.type.versionpublishedVersion-
hcfmusp.author.externalPRECIOSO, Alexander R.:Fundacao Butantan, Inst Butantan, Sao Paulo, Brazil-
hcfmusp.author.externalTIMENETSKY, Maria do Carmo S.:Univ Sao Paulo, Fac Med, Inst Adolfo Lutz, Sao Paulo, Brazil-
hcfmusp.description.beginpageS928-
hcfmusp.description.endpageS929-
hcfmusp.description.issue10-
hcfmusp.description.issuesuppl S-
hcfmusp.description.volume64-
hcfmusp.origemWOS-
hcfmusp.origem.idWOS:000309748305115-
hcfmusp.publisher.cityHOBOKEN-
hcfmusp.publisher.countryUSA-
dc.description.indexMEDLINE-
hcfmusp.remissive.sponsorshipFAPESP-
Appears in Collections:

Comunicações em Eventos - FM/MCM
Departamento de Clínica Médica - FM/MCM

Comunicações em Eventos - HC/ICHC
Instituto Central - HC/ICHC

Comunicações em Eventos - LIM/17
LIM/17 - Laboratório de Investigação em Reumatologia


Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.